{
  "company": "CIPLA",
  "report_date": "May 14, 2021",
  "filename": "CIPLA_transcript_May_2021.pdf",
  "quarter": "Q4",
  "fiscal_year": "2021",
  "management_team": [
    "MR. UMANG VOHRA - MD & GLOBAL CEO, CIPLA",
    "MR. KEDAR UPADHYE - GLOBAL CFO, CIPLA",
    "MR. NAVEEN BANSAL - INVESTOR RELATIONS TEAM,",
    "UMANG VOHRA - MD & GLOBAL CEO, CIPLA",
    "KEDAR UPADHYE - GLOBAL CFO, CIPLA",
    "NAVEEN BANSAL - INVESTOR RELATIONS TEAM,"
  ],
  "moderator": "MR",
  "analysts": [
    {
      "name": "Prakash",
      "firm": "Axis Capital"
    },
    {
      "name": "Nitya Balasubramanyam",
      "firm": "Bernstein"
    },
    {
      "name": "Niraj Khetan",
      "firm": "VT Capital"
    },
    {
      "name": "Neha Manpuria",
      "firm": "JP Morgan"
    },
    {
      "name": "Nimish Mehta",
      "firm": "Research Delta Advisors"
    },
    {
      "name": "Sameer Baisiwala",
      "firm": "Morgan Stanley"
    },
    {
      "name": "Charulata Gaidhani",
      "firm": "Dalal & Broacha"
    },
    {
      "name": "Krishnendu Shah",
      "firm": "Quantum Mutual Fund"
    },
    {
      "name": "Surya Patra",
      "firm": "PhillipCapital"
    },
    {
      "name": "Arpit Kapoor",
      "firm": "IDFC Mutual Fund"
    }
  ],
  "qa_segments": [],
  "key_financial_metrics": {
    "growth_percentage": "5",
    "increase_percentage": "2",
    "ebitda_margin_percentage": "22",
    "ebitda_inr_crores": "796"
  },
  "business_highlights": [
    "launched an active program to transition consumer brands to the CHL \nbusiness.",
    "partnership with \nMSD for Molnupiravir, Roche for the anti-body cocktail and El Lilly for Baricitinib.",
    "partnerships that we can have if people are interested to partner with us."
  ],
  "extraction_metadata": {
    "extraction_date": "2025-08-03T01:08:53.857438",
    "source_file": "data\\cipla\\CIPLA_transcript_May_2021.pdf",
    "text_length": 48359,
    "extraction_method": "PyMuPDF + Regex parsing + Filename analysis"
  }
}